Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Tomasz Switaj"'
Autor:
Piotr Rutkowski, Beata Jagielska, Jolanta Andrzejuk, Elzbieta Bylina, Iwona Lugowska, Tomasz Switaj, Hanna Kosela-Paterczyk, Katarzyna Kozak, Slawomir Falkowski, Anna Klimczak
Publikováno v:
Contemporary Oncology, Vol 21, Iss 4, Pp 285-289 (2017)
Aim of the study was to analyze the outcome of treatment and factors predicting results of sorafenib therapy in inoperable/metastatic CD117-positive GIST patients after failure on imatinib and sunitinib. Material and methods : We identified 60 consec
Externí odkaz:
https://doaj.org/article/86e1d9babcf8469d81cd7228127e973e
Publikováno v:
Sarcoma, Vol 2011 (2011)
The molecular pathogenesis of dermatofibrosarcoma protuberans (DFSP) involves distinctive rearrangement of chromosomes 17 and 22 leading to formation of the COL1A1-PDGFB fusion gene. The knowledge of molecular events underlying development of DFSP re
Externí odkaz:
https://doaj.org/article/7d4249748f5043b8b5c6e94810e76e70
Autor:
Joanna Kalisz, Natalia Krawczynska, Tomasz Switaj, Katarzyna Kozak, Małgorzata Chłopek, Monika Jurkowska, Janusz Limon, Aleksandra Gos, Piotr Rutkowski, Paweł Teterycz, Hanna Koseła-Paterczyk, Artur Kowalik, Iwona Lugowska, Janusz A. Siedlecki, Anna Klimczak, Bartosz Wasag
Publikováno v:
Tumori Journal. 106:241-248
Objective: We assessed the status of the BRAF V600E mutation in cell-free circulating tumor DNA (cfDNA) isolated from the plasma of patients with metastatic melanoma treated with the BRAF inhibitor vemurafenib, collected at different time points duri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::416528782e173a1a30fb86f5bdf5f67a
https://doi.org/10.1177/0300891619900928
https://doi.org/10.1177/0300891619900928
Autor:
Che-Jui Lee, Michael G Leahy, Tomasz Switaj, Maria Debiec-Rychter, Sandra J. Strauss, Axelle Nzokirantevye, Anouk Neven, Bernd Kasper, Frank M. Speetjens, Antoine Italiano, Michaela Kubickova, Veit Bücklein, Raf Sciot, Agnieszka Wozniak, Jean-Yves Blay, Patrick Schöffski, Silvia Stacchiotti, Nicolas Isambert
Publikováno v:
European Journal of Cancer, 156, 12-23. ELSEVIER SCI LTD
Purpose: European Organisation for Research and Treatment of Cancer (EORTC) 90101 (CREATE) was a prospective, multicentric, non-randomised, open-label phase II bas-ket trial to assess the efficacy and safety of crizotinib in patients with different t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45055c32098ebc01108b74d5cdcfc489
https://pubmed.ncbi.nlm.nih.gov/34392187
https://pubmed.ncbi.nlm.nih.gov/34392187
Autor:
Tomasz Switaj, Paweł Rogala, Iwona Lugowska, Piotr Rutkowski, Anna M. Czarnecka, Anna Mariuk-Jarema, Monika Dudzisz-Sledz, Paweł Teterycz
Publikováno v:
Targeted Oncology. 14:729-742
Although BRAF/MEK inhibitors are generally considered to be equally effective whether given before or after immunotherapy, no prospective trial has confirmed this hypothesis and contradictory data have been published in the melanoma field. We aimed t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcedb2c1c96b36e4e2d7e14e32966bba
https://doi.org/10.1007/s11523-019-00688-8
https://doi.org/10.1007/s11523-019-00688-8
Autor:
Bozena Cybulska-Stopa, Anna Malgorzata Czarnecka, Krzysztof Ostaszewski, Karolina Piejko, Marcin Zietek, Robert Dziura, Ewa Rutkowska, Łukasz Galus, Jacek Calik, Agata Sałek-Zań, Tomasz Zemelka, Agnieszka Kamycka, Wieslaw Bal, Tomasz Kubiatowski, Pawel Rogala, Tomasz Switaj, Grazyna Kaminska-Winciorek, Rafał Suwiński, Jacek Mackiewicz, Piotr Rutkowski
Publikováno v:
Journal of Clinical Oncology. 40:e21544-e21544
e21544 Background: BRAF-mutated (MUT) melanoma is characterized by specific clinical features including more aggressive biological behavior than BRAF wild-type (WT) melanoma. BRAF mutations are historically known as negative prognostic factor for to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5fa733a458d2a8069e435a14308a5a57
https://doi.org/10.1200/jco.2022.40.16_suppl.e21544
https://doi.org/10.1200/jco.2022.40.16_suppl.e21544
Autor:
Bozena Cybulska-Stopa, Anna Malgorzata Czarnecka, Krzysztof Ostaszewski, Karolina Piejko, Marcin Zietek, Robert Dziura, Ewa Rutkowska, Łukasz Galus, Barbara Ziolkowska, Natasza Kempa-Kamińska, Joanna Seredyńska, Agnieszka Kamycka, Wieslaw Bal, Anna Surus-Hyla, Tomasz Switaj, Pawel Rogala, Grazyna Kaminska-Winciorek, Rafał Suwiński, Jacek Mackiewicz, Piotr Rutkowski
Publikováno v:
Journal of Clinical Oncology. 40:e21539-e21539
e21539 Background: The use of targeted therapies (TT) and checkpoint inhibitors (IT) significantly prolonged survival in patients with metastatic melanoma, especially in patients with BRAF mutation-positive melanoma. Optimal sequence of therapies use
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0821bf030f85619f460aa933100a4abe
https://doi.org/10.1200/jco.2022.40.16_suppl.e21539
https://doi.org/10.1200/jco.2022.40.16_suppl.e21539
Autor:
Katarzyna, Kozak, Artur, Kowalik, Aleksandra, Gos, Bartosz, Wasag, Iwona, Lugowska, Monika, Jurkowska, Natalia, Krawczynska, Hanna, Kosela-Paterczyk, Tomasz, Switaj, Paweł, Teterycz, Anna, Klimczak, Janusz A, Siedlecki, Małgorzata, Chlopek, Joanna, Kalisz, Janusz, Limon, Piotr, Rutkowski
Publikováno v:
Tumori.
We assessed the status of thecfDNA in patients withcfDNA V600E was detected in the plasma of 48/62 (77%) patients at baseline and in 18/62 (29%) patients after 4-8 weeks of treatment. Patients positive forMonitoring of plasma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e9d0ca0be8a0d79ab086cf500b73f45b
https://pubmed.ncbi.nlm.nih.gov/32026754
https://pubmed.ncbi.nlm.nih.gov/32026754
Autor:
Piotr Rutkowski, Monika Dudzisz-Śledź, Pawel Sobczuk, Katarzyna Kozak, Tomasz Switaj, Hanna Kosela-Paterczyk, Anna Malgorzata Czarnecka, Slawomir Falkowski, Pawel Rogala, Tadeusz Morysinski, Mateusz Spalek, Marcin Zdzienicki, Tomasz Goryn, Marcin Zietek, Bozena Cybulska-Stopa, Stanislaw Klek, Grazyna Kaminska-Winciorek, Barbara Ziolkowska, Anna Szumera-Cieckiewicz
Publikováno v:
European Journal of Surgical Oncology. 48:e145
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28e7ffca91c17a21f08fb7aa072b31cb
https://doi.org/10.1016/j.ejso.2021.12.281
https://doi.org/10.1016/j.ejso.2021.12.281
Autor:
Monika Dudzisz-Sledz, Paweł Sobczuk, Katarzyna Kozak, Tomasz Switaj, Hanna Kosela-Paterczyk, Anna Malgorzata Czarnecka, Slawomir Falkowski, Paweł Rogala, Tadeusz Morysinski, Mateusz Jacek Spalek, Marcin Zdzienicki, Tomasz Goryn, Marcin Zietek, Bozena Cybulska-Stopa, Stanisław Klek, Grazyna Kaminska-Winciorek, Barbara Ziolkowska, Anna Szumera-Cieckiewicz, Piotr Rutkowski
Publikováno v:
Cancers; Volume 14; Issue 2; Pages: 422
Cancers, Vol 14, Iss 422, p 422 (2022)
Cancers
Cancers, Vol 14, Iss 422, p 422 (2022)
Cancers
Simple Summary Merkel cell carcinoma (MCC) is a rare skin cancer with unfavorable outcomes. Surgery remains the standard of care in the treatment of locally advanced disease. Perioperative radiotherapy and chemotherapy can be considered in selected p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdda912ba6e8613612b369641274feba
https://doi.org/10.3390/cancers14020422
https://doi.org/10.3390/cancers14020422